Back to Search
ANDREW TUCK, MD
MD
Psychiatry Physician
NPI: 1386208577IndividualAccepts Medicare
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
2023-01481(NC)
CMS Specialties
PrimaryPSYCHIATRY
Education
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Class of 2019
Research & Publications (20)
Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management.
PMID 17721886·J Cell Biochem·2007
6-review
Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
PMID 12606946·Oncogene·2003
8-other
The role of osteopontin in breast cancer: clinical and experimental studies.
PMID 12013531·J Mammary Gland Biol Neoplasia·2001
6-review
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.
PMID 19325010·Clin Chem·2009
4-observational
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
PMID 18437556·Breast Cancer Res Treat·2009
8-other
Effect of anti-fibrinolytic therapy on experimental melanoma metastasis.
PMID 19082867·Clin Exp Metastasis·2009
7-preclinical
Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment.
PMID 19578743·Int J Oncol·2009
7-preclinical
Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches.
PMID 19368727·BMC Pulm Med·2009
4-observational
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
PMID 18097747·Breast Cancer Res Treat·2008
7-preclinical
Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis.
PMID 18262045·Cancer Genet Cytogenet·2008
8-other
Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.
PMID 18638373·Breast Cancer Res·2008
8-other
Reconstitution and analysis of the multienzyme Escherichia coli RNA degradosome.
PMID 18691600·J Mol Biol·2008
8-other
Distinct karyotypes in three breast cancer cell lines --21PTCi, 21NTCi, and 21MT-1 --derived from the same patient and representing different stages of tumor progression.
PMID 18786440·Cancer Genet Cytogenet·2008
4-observational
Kinetic studies on the formation of DNA triplexes containing the nucleoside analogue 2'-O-(2-aminoethyl)-5-(3-amino-1-propynyl)uridine.
PMID 18075656·Org Biomol Chem·2008
8-other
A metric method for sex determination using the proximal femur and fragmentary hipbone.
PMID 18717754·J Forensic Sci·2008
8-other
Serial plasma osteopontin levels have prognostic value in metastatic breast cancer.
PMID 16740755·Clin Cancer Res·2006
8-other
Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy.
PMID 16807238·J Biol Chem·2006
8-other
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.
PMID 16816376·Am J Pathol·2006
7-preclinical
Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast.
PMID 16897748·Genes Chromosomes Cancer·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 72 JUSTIN CT
DURHAM, NC 27705 - Phone
- (231) 499-8276
Quick Facts
- NPI
- 1386208577
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 7
- Publications
- 20
Are you this provider?
Claim Your Profile